![AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II](https://ala.associates/wp-content/uploads/2022/04/AdBio-partners-team-1080x675.jpg)
![AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II](https://ala.associates/wp-content/uploads/2022/04/AdBio-partners-team-1080x675.jpg)
![Ribonexus receives €2M in deep tech financing from Bpifrance](https://ala.associates/wp-content/uploads/2022/04/Alejo-Chorny-COO-Ribonexus-1080x675.jpg)
Ribonexus receives €2M in deep tech financing from Bpifrance
![CardioRenal raises €3.3 million](https://ala.associates/wp-content/uploads/2022/03/CardioRenal-Tenor-technology-1.png)
CardioRenal raises €3.3 million
![SeaBeLife receives close to €1.4M deep tech financing from Bpifrance](https://ala.associates/wp-content/uploads/2022/03/ROUSSELOT-Morgane-©David-LevronBrest-metropole-1-1080x675.jpg)
SeaBeLife receives close to €1.4M deep tech financing from Bpifrance
![CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth call for Hospital-University Research in Health (RHU) projects](https://ala.associates/wp-content/uploads/2022/01/Domain-Therapeutics-image-1080x572.png)
CONDOR project for precision medicine and sarcoma immunotherapy awarded close to €10M in the fifth call for Hospital-University Research in Health (RHU) projects
![Spartha Medical receives €2.4M in financing from European Innovation Council](https://ala.associates/wp-content/uploads/2022/01/Spartha-4321-1080x675.jpg)
Spartha Medical receives €2.4M in financing from European Innovation Council
Spartha Medical receives €2.4M in financing from EIC
![Biomunex Pharmaceutical’s breakthrough immunotherapy project receives grants close to €3 Million](https://ala.associates/wp-content/uploads/2021/11/PE-Gerard-e1558960033209-1-e1635952448917.jpg)
Biomunex Pharmaceutical’s breakthrough immunotherapy project receives grants close to €3 Million
Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies
![EXCIVA raises €9 Million in series a round led by Andera Partners](https://ala.associates/wp-content/uploads/2021/11/CONQUET-Francois-1-scaled-1-e1637664095532.jpg)
EXCIVA raises €9 Million in series a round led by Andera Partners
German-based startup attracts venture funding from leading European VC firms to address ‘Agitation/Aggression’ in Alzheimer’s disease
![GTP Bioways invests € 12M in two GMP biopharmaceutical production units](https://ala.associates/wp-content/uploads/2021/11/gtpbiowaysseptembre-e1634886202588.jpg)
GTP Bioways invests € 12M in two GMP biopharmaceutical production units
GTP Bioways strengthens position as leading CDMO in Europe by opening two new biopharmaceutical production units at Toulouse site
GTP Bioways will become the unique CDMO in France with this offer, based on two new lines, one focused on microbial production, the other on small-scale mammalian-based production
![ADVENT FRANCE BIOTECHNOLOGY LAUNCHES ITS SECOND FUND WITH A FIRST CLOSE AT €86M ($102M)](https://ala.associates/wp-content/uploads/2021/12/Alain-Huriez-couleur-3-pdf-2.jpg)
ADVENT FRANCE BIOTECHNOLOGY LAUNCHES ITS SECOND FUND WITH A FIRST CLOSE AT €86M ($102M)
• Strong first closing confirms relevance of AFB’s unique early-stage investment strategy; aiming to create, develop and finance promising European life sciences startups in innovative therapeutics
• Since 2017, AFB’s €68M ($80M) first fund – Advent France Biotechnology Seed-Fund I – has successfully financed 15 startups in France, Spain, Belgium and Ireland